Date: 2017-09-22
Type of information: Loan
Company: DaVolterra (France)
Investors: European Investment Bank (EIB)
Amount: € 20 million
Funding type: loan
Planned used:
- The loan will be used to finance Da Volterra’s clinical developments in the area of prevention and treatment of antibiotic-resistant serious infectious and hospital-acquired diseases. The company’s most advanced product, DAV132, is being developed to prevent Clostridium difficile infections and the emergence of resistant bacteria in at-risk patients by protecting intestinal flora from antibiotic-induced disruption. The product has already been tested in four clinical trials and has demonstrated the proof of concept of protection of intestinal microbiota from antibiotic dysbiosis.
Others:
- • On September 22, 2017, the European Investment Bank (EIB) and biopharmaceutical company Da Volterra announced that they have entered into a € 20m financing agreement. This is a key loan designed to finance Da Volterra’s clinical developments in the area of prevention and treatment of antibiotic-resistant serious infectious and hospital-acquired diseases. The EIB support for Da Volterra’s development is being provided under the Horizon 2020 initiative, and more particularly the InnovFin Infectious Diseases Finance Facility, which offers bespoke products for financing high-risk projects in the field of infectious diseases. This instrument funds the development of vaccines, medicines, medical and diagnostic equipment and research facilities.
Therapeutic area: Infectious diseases
Is general: Yes
